Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 55

Results For "IMA"

3519 News Found

Sanofi's Q3 profit dips marginally as Dupixent sales top €4 billion
News | October 27, 2025

Sanofi's Q3 profit dips marginally as Dupixent sales top €4 billion

The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year


Telangana targets Rs.1 lakh crore investments in Life Sciences by 2030
News | October 27, 2025

Telangana targets Rs.1 lakh crore investments in Life Sciences by 2030

Telangana aims to increase the value of the Life Sciences economy from US$ 80 billion to US$ 250 billion by 2030


Quest Diagnostics reports strong third quarter 2025 results and raises full-year guidance
News | October 25, 2025

Quest Diagnostics reports strong third quarter 2025 results and raises full-year guidance

Revenues up 13.1% year-over-year; Continued momentum driven by organic growth, strategic partnerships, and acquisitions


Sanofi’s Efdoralprin Alfa shows superiority in phase 2 Alpha-1 antitrypsin deficiency study
Clinical Trials | October 25, 2025

Sanofi’s Efdoralprin Alfa shows superiority in phase 2 Alpha-1 antitrypsin deficiency study

Efdoralprin Alfa was well tolerated, with a safety profile comparable to plasma-derived therapy


Cipla to sell Lilly's weight-loss drug under new brand in India
News | October 24, 2025

Cipla to sell Lilly's weight-loss drug under new brand in India

Tirzepatide is a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors


Caplin Steriles receives FDA approval for ANDA Nicardipine Hydrochloride in 0.9% Sodium Chloride injection
Drug Approval | October 24, 2025

Caplin Steriles receives FDA approval for ANDA Nicardipine Hydrochloride in 0.9% Sodium Chloride injection

Nicardipine Hydrochloride in 0.9% Sodium Chloride Injection is indicated for the short-term treatment of hypertension when oral therapy is not feasible or desirable


Glenmark Pharmaceuticals USA to launch Ropivacaine Hydrochloride Injection USP
News | October 23, 2025

Glenmark Pharmaceuticals USA to launch Ropivacaine Hydrochloride Injection USP

Glenmark’s Ropivacaine Hydrochloride Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug Naropin Injection of Fresenius Kabi USA


Enzalutamide leads to 40% lower risk of death in prostate cancer
Clinical Trials | October 22, 2025

Enzalutamide leads to 40% lower risk of death in prostate cancer

XTANDI is the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in this patient population, supporting its earlier use in this setting


Pfizer’s Braftovi+Mektovi shows sustained long-term survival in patients with advanced lung cancer
Clinical Trials | October 22, 2025

Pfizer’s Braftovi+Mektovi shows sustained long-term survival in patients with advanced lung cancer

Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population


Qure.ai receives regulatory clearance for AI tool for early detection of TB in children below 3 years
Technology | October 22, 2025

Qure.ai receives regulatory clearance for AI tool for early detection of TB in children below 3 years

Breakthrough expands proactive TB screening from birth to 15 years, ensuring faster and more accurate diagnosis